Trial
NCT07388563
Azacitidine and Abatacept in Relapsed or Refractory T-Cell Lymphoma
Phase ISUSPENDEDOPERATIONALConfidence: HIGH
Sponsor
National Cancer Institute (NCI)
Collaborators
—
Condition
Lymphoma, T Cell, Peripheral
Intervention
azacitidine
Why stopped
New recruitment on hold for a protocol design amendment/modification.
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2026-05-08